2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116565
    Usmarapride 1428862-33-2 ≥98.0%
    Usmarapride (SUVN-D4010) is a potent, selective, orally active and brain penetrant 5-HT4 receptor partial agonist (EC50=44 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease.
    Usmarapride
  • HY-119934
    NaV1.7 inhibitor-1 1494585-79-3 99.65%
    NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC50 of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5.
    NaV1.7 inhibitor-1
  • HY-123534
    CYT-1010 213769-33-6 99.74%
    CYT-1010 is a mu-opioid receptor agonist extracted from patent WO2013173730A2, with EC50s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively.
    CYT-1010
  • HY-124607
    (R)-BRD3731 2056262-08-7 98.22%
    (R)-BRD3731 is a GSK3 inhibitor extracted from patent US20160375006A1, compound example 273, has IC50s of 1.05 and 6.7 μM for GSK3β and GSK3α, respectively.
    (R)-BRD3731
  • HY-128656
    LML134 1542135-76-1 99.43%
    LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders.
    LML134
  • HY-132310
    MAGL-IN-4 2135785-20-3 99.91%
    MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain.
    MAGL-IN-4
  • HY-133011
    nAChR agonist 1 1394371-75-5 98.35%
    nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC50 of 0.32 µM in a Ca2+ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease.
    nAChR agonist 1
  • HY-137447
    Pirepemat 1227638-29-0 98%
    Pirepemat (IRL752) is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat (IRL752) is used for the study of Parkinson's disease. IRL752 is a selective enhancer of cortical dopamine, acetylcholine and norepinephrine.
    Pirepemat
  • HY-14543S
    Sertindole-d4 1794737-42-0 98.64%
    Sertindole-d4 is the deuterium labeled Sertindole. Sertindole, a neuroleptic, is one of the newer antipsychotic medications available.
    Sertindole-d4
  • HY-145558
    Bliretrigine 1233229-75-8 99.42%
    Bliretrigine is a sodium channel blocker. Bliretrigine has the effect of relieving pain.
    Bliretrigine
  • HY-148176
    ANEB-001 791848-71-0 98%
    ANEB-001 is an orally active CB1 inhibitor, can be used to research acute cannabinoid intoxication.
    ANEB-001
  • HY-153369
    BAY-747 1609342-18-8 98%
    BAY-747 (BAY 1165747) is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model.
    BAY-747
  • HY-16009B
    Buntanetap L-Tartrate 865795-23-9 98.93%
    Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC50 = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease.
    Buntanetap L-Tartrate
  • HY-160604
    Remacemide 128298-28-2 98%
    Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research.
    Remacemide
  • HY-16723A
    (R)-Funapide 1259933-15-7 98.05%
    (R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel Nav1.7, Nav1.8 and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent.
    (R)-Funapide
  • HY-17382B
    Metoclopramide hydrochloride 7232-21-5 99.96%
    Metoclopramide hydrochloride is a potent and orally active antagonist of 5-HT3 and dopamine D2 receptor, with IC50s of 308 nM and 483 nM, respectively. Metoclopramide hydrochloride can be used for the research of nausea and vomiting, gastro-oesophageal reflux, and gastroparesis.
    Metoclopramide hydrochloride
  • HY-B0007C
    Baclofen hydrochloride 28311-31-1 99.20%
    Baclofen hydrochloride, a lipophilic derivative of γ-aminobutyric acid (GABA), is an orally active, selective metabotropic GABAB receptor (GABABR) agonist. Baclofen hydrochloride mimics the action of GABA and produces slow presynaptic inhibition through the GABAB receptor. Baclofen hydrochloride has high blood brain barrier penetrance. Baclofen hydrochloride has the potential for muscle spasticity research.
    Baclofen hydrochloride
  • HY-B1417S
    Nortriptyline-d3 hydrochloride 203784-52-5 99.75%
    Nortriptyline-d3 (hydrochloride) is the deuterium labeled Nortriptyline hydrochloride. Nortriptyline hydrochloride (Desmethylamitriptyline hydrochloride) is a tricyclic antidepressant and the main active metabolite of Amitriptyline, and used to relieve the symptoms of depression.
    Nortriptyline-d3 hydrochloride
  • HY-P99695
    Lerdelimumab 285985-06-0
    Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research.
    Lerdelimumab
  • HY-100714C
    DL-AP5 sodium 1303993-72-7 99.20%
    DL-AP5 (2-APV) sodium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 sodium shows significantly antinociceptive activity. DL-AP5 sodium specifically blocks on channels in the rabbit retina.
    DL-AP5 sodium
Cat. No. Product Name / Synonyms Application Reactivity